Mobile support lowered symptom burden in hemodialysis patients over 8 weeks
A mobile health intervention eased symptom burden and improved adherence in people receiving hemodialysis, offering a practical signal that digital coaching can matter in a population where daily treatment demands are relentless. In this randomized controlled trial, 68 patients at two hemodialysis centers in eastern Turkey were assigned equally to the app-based program or routine care, and all completed the 8-week follow-up.
The intervention was not a simple reminder tool. It combined five educational modules delivered through text, images, and videos with two automated reminders each day and researcher counseling delivered within 8 hours of a patient’s request. That design matters at the bedside because symptom management in dialysis is rarely about a single intervention; it is usually about reinforcing knowledge, supporting behavior, and reducing the drift that develops between treatment sessions.
After adjustment for baseline values, symptom burden was lower in the intervention arm, with an adjusted mean difference of −14.64 and a 95% confidence interval from −20.36 to −8.92. The probability value was below 0.001. Adherence also improved, with higher scores on the End-Stage Renal Disease Adherence Questionnaire; the adjusted difference was 75.24, with a 95% confidence interval from 28.04 to 122.44 and a P value of 0.002.
The intervention reached beyond patient-reported outcomes. Exploratory analyses favored the mobile app for interdialytic weight gain, ultrafiltration volume, phosphorus, and weight. Interdialytic weight gain fell by 0.48 kg, ultrafiltration volume by 449.11 mL, phosphorus by 1.20 mg/dL, and weight by 0.62 kg, with all four measures meeting statistical significance in the report. Those findings suggest the program may have improved day-to-day self-management in ways that translated into measurable dialysis-related changes.
A structured app can influence behavior between dialysis sessions
For patients on hemodialysis, the hardest clinical work often happens away from the machine. Fluid restriction, dietary discipline, medication routines, and symptom reporting all depend on what happens between treatments, when patients are managing fatigue, discomfort, and the friction of chronic illness on their own. A mobile platform can close part of that gap by placing education and reminders in the same device many patients already carry throughout the day.
The trial’s structure fits that logic. The educational modules addressed self-management directly, while the reminders and counseling offered repeated prompts and timely human contact. In chronic kidney disease care, that combination may be especially relevant because adherence failures often accumulate gradually rather than appearing as a single dramatic lapse. A patient who drinks slightly more fluid, misses a dietary restriction, or delays a response to symptoms may not feel the consequence immediately, but the dialysis prescription absorbs the effect later through larger ultrafiltration needs or worse biochemical control.
The observed reductions in ultrafiltration volume and interdialytic weight gain align with that clinical pattern. Lower fluid accumulation between treatments can ease the mechanical burden on dialysis sessions and may reduce the strain patients experience when large fluid shifts are required. The fall in phosphorus is also clinically relevant because dietary and medication adherence are central to phosphorus control in dialysis care. These were exploratory measures, not primary endpoints, yet they point toward a coherent behavioral effect rather than isolated statistical noise.
The trial was small, but the signal was consistent
The study enrolled 68 patients and followed them for only 8 weeks. That short horizon limits what can be said about durability, long-term hospitalization risk, vascular access outcomes, or whether adherence gains persist after the novelty of the app fades. The sample also came from two centers in eastern Turkey, which narrows how confidently the findings can be extended to different health systems, age groups, or digital literacy levels.
Even so, the results moved in the same direction across the main clinical and exploratory measures. The intervention arm did not merely report feeling better; it also showed better adherence scores and more favorable dialysis-related parameters. In a field where symptom burden can undermine self-management, that alignment is clinically meaningful.
The intervention itself was modest in concept and potentially scalable in practice. Five educational modules, two automated reminders each day, and fast access to counseling do not require highly specialized infrastructure. What they do require is a workflow that recognizes how often dialysis care fails in the intervals between scheduled treatments. For programs already managing heavy patient loads, a digital layer that reinforces education and offers responsive support may be easier to deploy than traditional one-on-one counseling alone.
Symptom control and adherence remain intertwined in dialysis care
Symptom burden in hemodialysis is not a side issue. It can sap motivation, complicate treatment routines, and make dietary or medication adherence harder to sustain. The trial’s main result suggests that addressing symptoms and adherence together may be more effective than treating them as separate targets. When patients receive repeated instruction and the chance for timely counseling, the practical obstacles to self-care may become more manageable.
The study also raises a familiar question in digital health: whether the benefit comes from the app itself, the reminders, the counseling, or the combination of all three. The design does not separate those components, so the active ingredient cannot be isolated from the published data. What is clear is that the bundled intervention performed better than routine care over the short follow-up period.
ClinicalTrials.gov lists the study under NCT05322291. The findings warrant confirmation in larger trials with longer follow-up, broader settings, and outcomes that extend beyond symptom scores and short-term dialysis metrics. For now, the data support a cautious but direct conclusion: a structured mobile program can improve adherence and reduce symptom burden in hemodialysis patients, and the downstream clinical effects deserve a larger test.